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a b s t r a c t 
We report a case of occult Mycobacterium bovis left axillary-bifemoral bypass graft infection, with su- 
perimposed acute methicillin-susceptible Staphylococcus aureus (MSSA) infection in an 82 year old male 
following intravesicular bacillus Calmette–Guerin (BCG) for adjuvant therapy of urothelial cancer. The pa- 
tient underwent partial removal of the bypass graft and treated with antimycobacterial therapy—rifampin 
and isoniazid for 9 months, and intravenous cefazolin followed by oral cephalexin for chronic suppressive 
therapy for MSSA. This presentation highlights the need to consider indolent infection masquerading as 
mechanical erosion, even when an alternate infection is present. 
© 2016 Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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An 82 year old Caucasian male with aortic atherosclerosis and
eft axillary femoral bypass graft with a femorofemoral crossover,
resented to our institution with rigors, progressive weakness,
eight loss, and hypotension with an open wound over the graft.
e underwent aortobifemoral graft placement 28 years before,
ith subsequent bowel perforation and infection of the graft
ecessitating removal of the graft and placement of a left axillary
o iliac bypass graft 7 years later. Six year prior to presentation,
e underwent left nephroureterectomy and transurethral resection
f bladder tumor for a noninvasive grade 2 out of 3 papillary
rothelial carcinoma. He had evidence of recurrence 3 years prior
o presentation. Pathology revealed noninvasive grade 3 out of 3
arcinoma. He received bacillus Calmette–Guerin (BCG) therapy for
hree treatments weekly, every 6 months, with excellent response
o this therapy on repeat cystoscopies without evidence of tumor
n the bladder. 
Approximately 3 years later (2 months prior to presentation),
e noticed erythema and skin blisters over the graft without
ystemic symptoms. Of note, his last BCG therapy and cystoscopy
as 4 months prior. Several weeks later, he developed weakness,
oss of appetite, weight loss, and an open wound with purulent
rainage over the graft. In the following 1–2 weeks, he had fevers,
igors, progressive weakness and presented to the emergency∗ Corresponding author. Fax: + 1 507 255 7767. 
E-mail address: desimone.daniel@mayo.edu (D.C. DeSimone). 
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405-5794/© 2016 Published by Elsevier Ltd. This is an open access article under the CCepartment where he had a blood pressure of 70/40, temperature
8.3 °C, and a pulse rate 139 bpm. Blood cultures on admission
rew methicillin-susceptible Staphylococcus aureus (MSSA). A 
ound culture obtained from the graft also grew MSSA. He was
tarted on intravenous vancomycin and piperacillin/tazobactam.
hysical examination was remarkable for a 2 cm open lesion over
he left lateral abdomen through which the graft was visible with
 small surrounding area of erythema. Laboratory studies revealed
 white blood cell count of 10,700 cells/mm 3 (90% neutrophils),
emoglobin 11.1 g/dL, sodium 128 mmol/L, creatinine 0.9 mg/dL,
ST 43 U/L, ALT 33 U/L, and alkaline phosphatase 167 U/L. 
Ultrasound of the bypass graft and computer tomography
ngiogram of the abdominal aorta showed complete occlusion of
he left axillary to bilateral common femoral artery bypass graft
nd an open wound in the left ﬂank extending to the graft (see
ig. 1 ). An Indium-111 white blood cell scan revealed abnormal
adiotracer localization along the left axillary to left common
emoral artery graft consistent with an infected bypass graft.
e was diagnosed with S. aureus graft infection with secondary
loodstream infection. However, the subacute erythema over the
raft developing about 8 weeks prior to admission raised the
ossibility of a more indolent infection leading to graft erosion
hrough the skin. Given previous BCG therapy, disseminated BCG
nfection was also considered. 
The following day, he underwent explantation of the graft with
losure of the left axillary proximal anastomosis over a stump
f the graft, and closure of the distal right femoral anastomosis
nd left femoral anastomosis, leaving a small rim of incorporatedBY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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Fig. 1. Open wound in the left ﬂank extending to the graft. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Explanation of the infected left axillofemoral bypass graft. 
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rgraft (see Fig. 2 ). Transesophageal echocardiogram was performed
and did not show any evidence of valvular vegetations. Bacterial
cultures of the explanted graft revealed MSSA and antibiotic
therapy was narrowed to IV cefazolin to complete 4 weeks of
therapy followed by chronic oral antibiotic suppression with
cephalexin 500 mg twice daily, given the residual graft present.
Pathology of the graft material showed acutely inﬂamed ﬁbrous
tissue without identiﬁable microorganisms on tissue Gram and
Gomori methenamine silver stains. 
Approximately 2 weeks after explantation, mycobacterial cul-
tures grew Mycobacterium tuberculosis complex on 5 out of 5
surgical specimens obtained. Acid-fast smears were negative on
all cultures. Mycobacterial blood cultures remained negative at 60
days. Identiﬁcation by high-performance liquid chromatography
revealed Mycobacterium bovis , BCG strain. Susceptibilities demon-
strated resistance to pyrazinamide with mutation detected in
pncA on sequencing, and sensitivity to rifampin, ethambutol, and
isoniazid. He was treated with oral isoniazid and rifampin for 9
months. He was seen in follow up 3 months following completion
of antimycobacterial therapy and had no fevers or chills, and his
only complaint was claudication after walking two to three blocks.
Discussion 
We report a rare case of Mycobacterium bovis infection of
a vascular bypass graft in a patient receiving intravesical BCG
therapy. Our patient developed a skin and soft tissue infection
that progressed over an 8-week period with exposure of the
bypass graft and ultimately MSSA bloodstream infection. He was
treated with anti-staphylococcal antibiotic therapy and under-
went surgical removal of the graft. However, given the indolent
course, which would be unexpected for S. aureus , the provider
requested additional cultures (fungal, mycobacterial) considering
alternative diagnoses given the history of previous BCG therapy.
This ultimately led to our ﬁnding of M. bovis . We hypothesize
the patient developed BCG infection of the bypass graft that led
to subacute wound breakdown and exposure of the graft with
secondary infection from skin ﬂora (MSSA) leading to bacteremia.
Our patient improved following graft removal and antimicrobial
therapy—IV cefazolin for 4 weeks followed by chronic suppression
with oral cephalexin 500 mg twice a day, and oral isoniazid and
rifampin for 9 months. 
BCG is a live attenuated strain of Mycobacterium bovis that
has become the treatment of choice in patients with superﬁcial
urothelial cancer [1] . Intravesical BCG therapy reduces disease
progression, the need for cystectomy, and prolongs survival [2] .t is well tolerated by > 95% of patients. However, both local and
ystemic complications can occur following BCG therapy such as
ysuria, hematuria, fever, and malaise for up to 48 h following
nstillation [3,4] . The anti-neoplastic mechanism is thought to be
ue to immune stimulation of both cell-mediated immunity and
ytokines, which results in the death of cancer cells [2,3,5–7] . In
ne study of over 2600 patients, 4.8% of patients developed severe,
ystemic complications including sepsis, cytopenia, renal abscess,
neumonia, fever, and granulomatous prostatitis [2] . In an analysis
f 282 patients with BCG infection, disseminated BCG infection
miliary tuberculosis, fever with bone marrow and/or liver inﬁl-
ration, and sepsis with multiorgan failure) was the most common
anifestation, occurring in 34.4% of patients. Less common man-
festations included osteomuscular infection including prosthetic
oint infections (19.9%), hepatitis (5.7%), mycotic aneurysms (4.6%),
nd infection of a vascular bypass graft (0.7%) [3] . 
The risk proﬁle of patients who develop complications from
ntravesical BCG therapy is unknown. It has been suggested that
arly BCG instillation following disruption of the urothelial barrier,
resence of underlying immunosuppression, advanced age [6] ,
nd early BCG instillation after transurethral resection of bladder
ancer [3,8,9] . Our patient received intravesical BCG therapy for
pproximately 3 years, starting at the age of 79 and presented
ith BCG involvement of the vascular bypass graft at the age of
2. His last BCG instillation was approximately 4 months prior to
he development of infection. Heiner and Terris [6] caution against
roviding maintenance BCG therapy in patients 70 years and older,
nd suggest altogether avoidance in patients over age 80. 
There has been only one case report in the literature of M. bovis
nfection of an axillary-femoral bypass graft following intravesical
CG therapy [10] . This patient was a 62 year old male with non-
nvasive urothelial carcinoma who received BCG instillations over
 10 month period. He underwent removal of the bypass graft and
eceived isoniazid, rifampin, and ethambutol for 9 months [10] ;
owever, there was no follow-up available for their patient. Our
atient underwent surgical removal of the entire axillo-bifemoral
ypass graft except there was a small rim of incorporated graft.
he treatment course was 9 months for M. bovis with oral rifampin
nd isoniazid, and IV cefazolin followed by oral suppression with
ephalexin for MSSA. He was followed up in clinic 13 months
ost-hospitalization, doing well without fevers or chills. 
This case illustrates the importance of having a high-index of
uspicion for occult infection with BCG infection, even when an
lternate pathogen is present. Surgical explantation of the by-
ass graft, and anti-staphylococcal and antimycobacterial therapy,
esulted in a favorable outcome in this case. 
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